Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone and joint problems news

Show

From To
Primary care key to management of patients with HIV infection

The HIV Medicine Association of the Infectious Diseases Society of America has updated its HIV care guidelines to reflect the fact that people with HIV are now living normal life spans, and their physicians need to focus on preventive care, including screening for high cholesterol, diabetes and osteoporosis.

Published
14 November 2013
From
Eurekalert Inf Dis
TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

Published
19 September 2013
From
NATAP
Bone loss and fracture risk are 'modest' among HIV+ people, linked to tenofovir, smoking, and HCV

Continued bone loss among HIV positive men with osteopenia was modest overall, but about 25% of those taking tenofovir (Viread, also in 4 antiretroviral coformulations) experienced significant loss, according to a recent study. A related meta-analysis found that HIV infection is associated with a modest likelihood of new fractures, with smoking and hepatitis C virus (HCV) coinfection further increasing the risk.

Published
07 June 2013
From
HIVandHepatitis.com
Bone mineral density below normal in children infected early with HIV

Bone mineral density was below the general population norm in US children perinatally infected with HIV and lower than in children perinatally exposed to HIV but uninfected.

Published
21 January 2013
From
International AIDS Society
HIV treatment interruption associated with reduced bone loss in SMART trial

People who stopped antiretroviral therapy in the SMART trial had less bone loss and lower levels of bone metabolism biomarkers than people who remained on continuous antiretroviral therapy (ART), according to a report in the January 8, 2013, advance edition of Journal of Bone Mineral Research.

Published
16 January 2013
From
HIVandHepatitis.com
Activist discusses challenge of growing old with HIV

Old age comes faster and hits harder for those infected with HIV, a fact aging health activist Ron Swanda knows all too well.

Published
30 November 2012
From
AFP
Weekly alendronate improves bone density in adults taking ART

Alendronate significantly improved bone mineral density through 96 weeks of treatment in a double-blind placebo-controlled trial that enrolled adults with osteoporosis while taking antiretroviral therapy (ART).

Published
30 August 2012
From
International AIDS Society
High Dose Vitamin D Prevents Fractures

High doses of vitamin D prevent fractures in older people – as long as they take the substance regularly.

Published
05 July 2012
From
Medical News Today
Treatment Update: Bone Health

Many studies have found that some HIV-positive people tend to have bones that are not as thick or dense as they ought to be. Such bones have reduced bone mineral density, as minerals such as calcium have been removed, rendering the bones more porous and weak.

Published
28 May 2012
From
CATIE
Bisphosphonate Drugs Linked to Atypical Femur Fractures, but Absolute Risk is Small

Use of bisphosphonates, a class of drugs used to manage bone loss and prevent fractures, actually appears to increase the likelihood of an unusual type of femur (thigh bone) fracture, according to a retrospective analysis described in the advance online edition of Archives of Internal Medicine. Researchers emphasized, however, that the absolute risk of atypical femur breaks remains very low.

Published
28 May 2012
From
HIVandHepatitis.com

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.